IDH1 and central nervous system cancer: Aside from IDH-mutant astrocytoma and H3.3-mutant glioma, glioblastoma (13–19%), oligodendroglioma (2%), and MAPK-altered tumors (2–7%) were consistently represented in both cohorts.